Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | HTR1F | P30939 | 2/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17645995 | 0.85 | TP53 (0.40) | NLRP3KMT2AFAAH | |
| SCHEMBL19556149 | 0.85 | QDPR (0.40) | GSK3BDYRK1ARIPK1KMT2AFAAH | |
| SCHEMBL14680766 | 0.84 | GSK3B (0.48) | GSK3BDYRK1ALRRK2HTR1AHTR1D | |
| SCHEMBL22617163 | 0.82 | CA12 (0.42) | NLRP3KMT2ASMN1; SMN2 | |
| SCHEMBL19556559 | 0.80 | POLB (0.35) | NLRP3KMT2AFAAH | |
| Lithium SCHEMBL31704760 | 0.78 | POLB (0.34) | NLRP3KMT2AFAAH | |
| SCHEMBL19556211 | 0.76 | TBK1 (0.35) | GSK3BDYRK1ANLRP3KMT2A | |
| SCHEMBL22860620 | 0.76 | LRRK2 (0.42) | GSK3BDYRK1ALRRK2PLGFAAH | |
| SCHEMBL31488376 | 0.70 | CA12 (0.42) | GSK3BDYRK1AKMT2AFAAH | |
| SCHEMBL20969081 | 0.70 | ENPP2 (0.44) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | NEUROPORE THERAPIES, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846682-B2 | Compound suitable for the treatment of synucleopathies | NEUROPORE THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130035342-A1 | Compound Suitable for the Treatment of Synucleopathies | NEUROPORE THERAPIES, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035342-A1 | Compound Suitable for the Treatment of Synucleopathies | SNCA, HTT, SMN1; SMN2 | GSK3B 341/4885DYRK1A 2057/4885LRRK2 15/4885 |
| US-20140364610-A1 | COMPOUND SUITABLE FOR THE TREATMENT OF SYNUCLEOPATHIES | SNCA, HTT, MAPT | GSK3B 332/4885DYRK1A 1581/4885LRRK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.